Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- Chuikyo Members Chide Unexplained Withdrawal of Taltz’s Listing Request
November 10, 2016
- MHLW Won’t Require Use of Other Psoriasis Drugs before Taltz
November 10, 2016
- MHLW Plans 50% Price Cut for Opdivo
November 10, 2016
- Chuikyo OKs Taltz, Micatrio for Listing on Nov. 18; Keytruda Takes Pass This Time
November 9, 2016
- LDP Lawmakers Discuss Re-Pricing of Opdivo; Some Say Application of Huge Seller Rule Reasonable
November 9, 2016
- Shiozaki Lauds BIKEN-Mitsubishi Vaccine JV
November 8, 2016
- PMDA Fastest in Granting New Drug Approvals
November 4, 2016
- PMDA Mulls Fee Raise for Drug, Device Reviews
November 4, 2016
- Medical Corporation in Tokyo Ordered to Temporarily Suspend Regenerative Medicine Service: MHLW
November 4, 2016
- MHLW Struggling to Set Date for Chuikyo Subcommittee Discussions on Opdivo
November 2, 2016
- MHLW Panel Backs Ono’s Hyperparathyroidism Drug Etelcalcetide
November 1, 2016
- PMDA Had 71 Individual Interviews in Regulatory Strategy Consultation Services in April-September 2016
November 1, 2016
- Inisync, 4 Other DPP-4 Inhibitors Under PMDA Risk Review
October 31, 2016
- Postponed PAFSC 2nd Committee Meeting Set for November 11
October 31, 2016
- MID-NET Working Group Discusses Access Fee Calculations
October 28, 2016
- Long-Listed Drug Use by Welfare Recipients Should Require Copay: MOF
October 28, 2016
- Panel Negative about Singling Out OTC-Switched Rx for Health Coverage Talks, Calls for Broader Discussions
October 27, 2016
- Shiozaki Does Not Rule Out Price Cut of Over 25% for Opdivo
October 27, 2016
- MHLW Alerts on Risk of Fulminant Type 1 Diabetes for Keytruda
October 25, 2016
- Pharma Groups Tender Requests to LDP on FY2017 Budget, Tax Reform
October 24, 2016
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…